- Home
- WGSWW vs PRVA Comparison
WGSWW vs PRVA Comparison
Compare WGSWW & PRVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGSWW
- PRVA
- Stock Information
- Founded
- WGSWW 2017
- PRVA 2007
- Country
- WGSWW United States
- PRVA United States
- Employees
- WGSWW N/A
- PRVA N/A
- Industry
- WGSWW Retail: Computer Software & Peripheral Equipment
- PRVA Retail: Computer Software & Peripheral Equipment
- Sector
- WGSWW Technology
- PRVA Technology
- Exchange
- WGSWW Nasdaq
- PRVA Nasdaq
- Market Cap
- WGSWW N/A
- PRVA N/A
- IPO Year
- WGSWW N/A
- PRVA 2021
- Fundamental
- Price
- WGSWW $0.21
- PRVA $22.45
- Analyst Decision
- WGSWW
- PRVA Strong Buy
- Analyst Count
- WGSWW 0
- PRVA 16
- Target Price
- WGSWW N/A
- PRVA $26.56
- AVG Volume (30 Days)
- WGSWW 36.6K
- PRVA 815.4K
- Earning Date
- WGSWW 02-18-2025
- PRVA 05-08-2025
- Dividend Yield
- WGSWW N/A
- PRVA N/A
- EPS Growth
- WGSWW N/A
- PRVA N/A
- EPS
- WGSWW N/A
- PRVA 0.11
- Revenue
- WGSWW $305,450,000.00
- PRVA $1,736,390,000.00
- Revenue This Year
- WGSWW N/A
- PRVA $88.90
- Revenue Next Year
- WGSWW N/A
- PRVA $10.98
- P/E Ratio
- WGSWW N/A
- PRVA $204.18
- Revenue Growth
- WGSWW 50.79
- PRVA 4.75
- 52 Week Low
- WGSWW $0.17
- PRVA $15.92
- 52 Week High
- WGSWW $0.21
- PRVA $26.04
- Technical
- Relative Strength Index (RSI)
- WGSWW N/A
- PRVA 38.58
- Support Level
- WGSWW N/A
- PRVA $22.51
- Resistance Level
- WGSWW N/A
- PRVA $22.97
- Average True Range (ATR)
- WGSWW 0.00
- PRVA 0.68
- MACD
- WGSWW 0.00
- PRVA -0.19
- Stochastic Oscillator
- WGSWW 0.00
- PRVA 19.40
About WGSWW GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.